drugset / Trial / NCT03862170

Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer

NCT03862170

Phase 3 Terminated 158 enrolled CR-CSSS Champlain-Charles-Le Moyne
RandomizedParallel-groupOpen-labelPrevention

Summary

Phase III study that aims to evaluate the necessity of prophylactic antibiotics use after HDR brachytherapy in the treatment of prostate adenocarcinomas.

Timeline

Start
2015-02-10
Primary completion
2020-02
Completion
2023-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefazolin Small molecule 2000 mg Intravenous
Comparator Ciprofloxacin Small molecule 400 mg Intravenous

Indications